Induction therapy with basiliximab and full HLA mismatch.

[1]  J. Joh,et al.  Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study. , 2012, Transplantation Proceedings.

[2]  Ethan M Balk,et al.  KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. , 2010, Kidney international.

[3]  A. Webster,et al.  Interleukin 2 receptor antagonists for kidney transplant recipients. , 2010, The Cochrane database of systematic reviews.

[4]  A. Cabrita,et al.  The influence of HLA mismatches and immunosuppression on kidney graft survival: an analysis of more than 1300 patients. , 2007, Transplantation proceedings.

[5]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[6]  S. Sandrini.  Use of IL‐2 receptor antagonists to reduce delayed graft function following renal transplantation: a review , 2005, Clinical transplantation.

[7]  Xuanming Su,et al.  Diminishing Significance of HLA Matching 
 in Kidney Transplantation , 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  L. Rostaing,et al.  Sequential Protocols using Basiliximab versus Anti-Thymocyte Globulins in Renal-Transplant Patients Receiving Mycophenolate Mofetil and Steroids , 2004, Transplantation.

[9]  J. Berlin,et al.  Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. , 1997, Journal of the American Society of Nephrology : JASN.